$5.050
+0.081 (+1.61%)Al cierre
Noticias de EMBC
Eventos de EMBC
embecta Reports Q3 Revenue of $271.7M
Reports Q3 revenue $271.7M, consensus $254.54M. "Our third quarter results improved significantly on a sequential basis, with revenue increasing approximately $50 million, GAAP operating income increasing approximately $14 million, and adjusted operating income increasing approximately $21 million as compared to our second quarter results. The sequential increase was due to a combination of factors, including improved performance within the United States and International, as well as contribution from the acquisition of Owen Mumford which closed mid-way through our third quarter," said Devdatt (Dev) Kurdikar, Chairman, President and Chief Executive Officer of embecta.
embecta Q2 Revenue $22.18M, Significantly Below Expectations
Reports Q2 revenue $22.18M, consensus $235.66M. "We were disappointed with our second quarter results as they were significantly below our expectations, driven by a combination of factors which impacted our U.S. business, including increased competitive dynamics and softness in overall market volumes. Our International business performed in line with expectations," said Devdatt Kurdikar, Chairman, President and CEO of embecta. Kurdikar continued, "Given our results, we have initiated a review of our cost structure and organizational footprint and expect to communicate findings and any resulting actions to investors once that process is complete. Our lowered financial guidance assumes that the dynamics which impacted our U.S. business during the second quarter will continue for the balance of the year, as well as the addition of Owen Mumford."
Lowers FY26 Revenue Outlook to $1.015B-$1.035B
Lowers FY26 revenue view to $1.015B-$1.035B from $1.071B-$1.093B. Consensus is for FY26 EPS $2.82 and for revenue $1.07B.
Embecta to Acquire Owen Mumford for Up to £150M
Embecta has entered into a definitive agreement to acquire Owen Mumford Holdings, a privately held, UK-based manufacturer of medical devices and drug-delivery technologies, in a transaction valued at up to GBP150M. embecta will acquire Owen Mumford for an upfront cash payment of GBP100M at closing and up to an additional GBP50M in performance-based payments based on net sales of the Aidaptus auto-injector platform in the three-year period following the closing. The transaction is expected to close in embecta's 3Q26, subject to regulatory approvals and satisfaction of other closing conditions. Owen Mumford's products include a pharmaceutical services portfolio built on historic autoinjector success with pharmaceutical companies and an outlook anchored by Aidaptus and other drug delivery devices. Owen Mumford also has a portfolio of medical devices across point-of-care testing, self-injection and pelvic health devices. Owen Mumford generated net revenue of GBP69.4M during FY25. embecta expects the acquisition to contribute to revenue growth in FY27 and beyond; to be immaterial to embecta's FY27 adjusted operating income and to be accretive thereafter; to be dilutive to adjusted net income in FY27, to be immaterial to embecta's FY28 adjusted net income and to be accretive thereafter; and to generate high-single-digit return on invested capital by year four, with increasing contribution thereafter. embecta plans to finance the closing purchase price with the proceeds of borrowings under its revolving credit facility.
Embecta Appoints Devdatt Kurdikar as Board Chairman
Embecta announced that the board of directors of Embecta has elected Devdatt Kurdikar as chairman of the board and Claire Pomeroy as lead independent director, effective immediately. These changes follow the previously announced retirement of David Melcher, non-executive chairman of the board due to several commitments outside of his service to the Company. Kurdikar joined Becton Dickinson in 2021 to lead the diabetes care business and became the president and CEO of the company and a member of its board of directors upon completion of its spinoff from BD in 2022.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.